[CAS NO. 3032997-12-6] CDK1-IN-3
PRODUCTS SPECIFICATIONS [3032997-12-6]
DESCRIPTION [3032997-12-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 555.98 |
| Molecular Formula | C28H25ClF3N5O2 |
| SMILES | O=C(N1CCN(C2=NN=C(CC3=CC=C(OC)C=C3)C4=C2C=CC=C4)CC1)NC5=CC=C(Cl)C(C(F)(F)F)=C5 |
Summary
IC50 & Target
|
CDK1 36.8 nM (IC 50 ) |
CDK2 305.17 nM (IC 50 ) |
CDK5 369.37 nM (IC 50 ) |
In Vitro
CDK1-IN-3 (0-10 μM; 24 h) inhibits the growth of PDAC, melanoma, leukemia, colon and breast cancer cells
[1]
.
CDK1-IN-3 (0-1 μM) inhibits CDK1, CDK2 and CDK5 with IC
50
s of 36.8, 305.17 and 369.37 nM, respectively
[1]
.
CDK1-IN-3 (0-10 μM) inhibits AXL, PTK2B, FGFR, JAK1, IGF1R and BRAF kinases with IC
50
s of 5655, 3632, 4626, 5265, 5514 and 2829 nM, respectively
[1]
.
CDK1-IN-3 (0.51 μM; 24 h) decreases CDK1 protein level in virto and affects cell cycle
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | PDAC, melanoma, leukemia, colon and breast cancer cell lines |
| Concentration: | 0-10 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited cell growth of PDAC, melanoma, leukemia, colon, and breast cancer cells over 61%, and inhibited MDA-PATC53 and PL45 cells with IC 50 s of 0.51 and 0.74 μM, respectively. |
Western Blot Analysis [1]
| Cell Line: | MDA-PATC53 cell line |
| Concentration: | 0.51 μM |
| Incubation Time: | 24 hours |
| Result: | Downregulated CDK1 protein level compared to untreated cells. |
Western Blot Analysis [1]
| Cell Line: | MDA-PATC53 cell line |
| Concentration: | 0.51 μM |
| Incubation Time: | 24 hours |
| Result: | Significantly arrested in G2/M phase of the cell cycle compared with the untreated cells. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.